Loading...

MedXY AI/MedXY News/Tag: oncology

MedXY News

EnglishTag

oncology

85 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders

Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders

A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-year

Section: General SurgeryJan 25, 2026

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.

Section: news

Jan 25, 2026

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo

Section: newsJan 20, 2026

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

Clinical trials evaluate elraglusib, a GSK-3β inhibitor, in salivary gland and pancreatic cancers. While results were mixed, findings highlight the importance of nuclear GSK-3β expression as a biomarker and the need for dose optimization to

Section: newsJan 20, 2026

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che

Section: newsJan 19, 2026

Distinct Histological Patterns in Anal Canal Cancer: Insights from the Japanese National Registry

Distinct Histological Patterns in Anal Canal Cancer: Insights from the Japanese National Registry

This article explores the unique epidemiological landscape of anal canal cancer in Japan, highlighting the predominance of adenocarcinoma over squamous cell carcinoma and the rising role of chemoradiotherapy in clinical management.

Section: GastroenterologyJan 15, 2026

$Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors$

Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors

A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multi

Section: newsJan 14, 2026

Global Gastrointestinal Cancer Burden to Nearly Double by 2050: A Critical Call for Targeted Prevention and Resource Allocation

Global Gastrointestinal Cancer Burden to Nearly Double by 2050: A Critical Call for Targeted Prevention and Resource Allocation

By 2050, global gastrointestinal cancer incidence is projected to surge by 85%, reaching 9.06 million cases annually. While gastric cancer rates are declining, colorectal and pancreatic cancers are rising sharply, particularly in low and me

Section: GastroenterologyJan 14, 2026

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l

Section: newsJan 13, 2026

$Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights$

Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights

This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise

Section: newsJan 13, 2026

SARC031 Trial: Why Combined MEK and mTOR Inhibition Failed to Translate from Mice to Men in MPNST

SARC031 Trial: Why Combined MEK and mTOR Inhibition Failed to Translate from Mice to Men in MPNST

The SARC031 Phase 2 trial evaluated selumetinib and sirolimus for advanced MPNST. Despite strong preclinical rationale, the combination showed minimal clinical benefit, though correlative studies on cfDNA and PET imaging offer vital insight

Section: newsJan 13, 2026

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial

A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.

Section: newsJan 13, 2026

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.

Section: newsJan 13, 2026

Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer

Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer

This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary tre

Section: newsJan 13, 2026

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?

A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quali

Section: newsJan 12, 2026

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma

Section: newsJan 12, 2026

Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

A Phase 2 study reveals that eribulin, a non-taxane microtubule inhibitor, provides meaningful objective responses and disease stability in patients with rare vascular sarcomas, including those previously treated with taxanes.

Section: newsJan 12, 2026

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.

Section: GastroenterologyJan 12, 2026

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre

Section: newsJan 9, 2026

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer

Section: newsJan 9, 2026

Prev 1 2 3 4 5 Next